このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism (STRATEGY-PE)

Real-World Comparative Effectiveness and Safety of Anticoagulation, Thrombolysis, and Mechanical Thrombectomy in Intermediate-Risk Acute Pulmonary Embolism: A Multicenter Prospective Cohort Study

This study aims to compare the effectiveness and safety of three treatment strategies (Anticoagulation, Thrombolysis, and Mechanical Thrombectomy) for patients with intermediate-high risk acute pulmonary embolism (PE) in a real-world setting. Approximately 1,300 patients will be enrolled across multiple centers in China. Patients will be followed for 90 days to assess mortality, heart function recovery, bleeding risks, and quality of life. The results will help guide personalized treatment decisions and healthcare policy.

調査の概要

詳細な説明

Background: Acute pulmonary embolism (PE) is a severe manifestation of venous thromboembolism (VTE). Intermediate-high risk PE accounts for 20-30% of all PE cases with significant mortality driven by right ventricular (RV) dysfunction. Current guidelines recommend anticoagulation for all, with thrombolysis or mechanical thrombectomy as rescue or alternative therapies. However, there is significant heterogeneity in real-world treatment selection and a lack of head-to-head comparative evidence among the three strategies in complex real-world populations.

Objective: To compare the 30-day and 90-day all-cause mortality and 48-hour RV/LV ratio improvement rate among three treatment strategies (Anticoagulation, Thrombolysis, Mechanical Thrombectomy) in patients with intermediate-high risk acute PE.

Design: This is a prospective, multicenter, non-randomized, pragmatic cohort study. Treatment allocation is based on routine clinical decision-making (natural allocation) without investigator intervention. Advanced statistical methods (Propensity Score Matching/Weighting, Instrumental Variable analysis) will be used to control for confounding factors.

Participants: 1,300 patients with confirmed acute intermediate-high risk PE (RV/LV ratio ≥0.9 and elevated cardiac biomarkers, hemodynamically stable). There are no age limits to reflect real-world diversity.

Interventions/Exposures:

  1. Anticoagulation (AC): Standard anticoagulant therapy (LMWH, DOAC, UFH, or Warfarin).
  2. Thrombolysis (TL): Systemic thrombolysis or Catheter-Directed Thrombolysis (CDT) using agents like Urokinase, Alteplase, etc.
  3. Mechanical Thrombectomy (MT): Mechanical removal of thrombus using FDA/NMPA approved devices (e.g., Indigo, FlowTriever, Acoscream), with or without adjunctive anticoagulation/thrombolysis.

Outcomes:

  • Primary: 30-day and 90-day all-cause mortality; 48-hour RV/LV ratio improvement rate (≥15% reduction).
  • Secondary: Clinical deterioration, major bleeding (ISTH/GUSTO/BARC), functional status (6MWT, NYHA, PVFS), quality of life (PEmb-QoL, EQ-5D-5L), PE recurrence, and healthcare resource utilization.

Follow-up: Patients will be followed at 48 hours, 7 days, 30 days, and 90 days.

研究の種類

観察的

入学 (推定)

1300

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:he xu Dr, doctor
  • 電話番号:+86 153 6611 0045
  • メール:kilogram@163.com

研究場所

    • Jiangsu
      • Nanjing、Jiangsu、中国、210006
        • Nanjing First Hospital
        • コンタクト:
          • Interventional Vascular Department Director, doctor
          • 電話番号:+86-25-52271000
          • メール:kilogram@163.com

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 子
  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

サンプリング方法

非確率サンプル

調査対象母集団

Patients diagnosed with intermediate-high risk acute pulmonary embolism admitted to participating tertiary hospitals with Pulmonary Embolism Response Teams (PERT).

説明

Inclusion Criteria:

  • Age unlimited (reflecting real-world population).
  • Symptom duration of acute PE ≤ 14 days.
  • Confirmed acute PE by CTPA involving main or lobar pulmonary arteries.
  • Defined as Intermediate-High Risk PE meeting all of the following:
  • RV/LV ratio ≥ 0.9 (by CT or Echocardiography).
  • Elevated cardiac biomarkers (Troponin > 99th percentile or BNP > 100 pg/mL).
  • Hemodynamically stable (SBP ≥ 90 mmHg, no vasopressors required).
  • Able to provide informed consent and complete follow-up.

Exclusion Criteria:

  • Already received thrombolysis or mechanical thrombectomy for the current episode prior to enrollment.
  • Unable to obtain baseline or follow-up CTPA imaging.
  • (Note: Unlike strict RCTs, patients with cancer, renal insufficiency, or advanced age are NOT excluded to ensure real-world representativeness).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
介入・治療
Anticoagulation Cohort
Patients receiving standard anticoagulation therapy alone without thrombolysis or mechanical thrombectomy.
Low Molecular Weight Heparin (LMWH), Direct Oral Anticoagulants (DOAC), Unfractionated Heparin (UFH), or Warfarin according to guideline-standard regimens.
他の名前:
  • Heparin, Enoxaparin, Rivaroxaban, Apixaban, Dabigatran, Edoxaban, Warfarin
Thrombolysis Cohort
Patients receiving systemic thrombolysis or catheter-directed thrombolysis.
Any FDA/NMPA approved mechanical thrombectomy device (e.g., Indigo, FlowTriever, Acoscream) used for clot removal.
他の名前:
  • Indigo Aspiration System, FlowTriever, Acostream
Mechanical Thrombectomy Cohort
Patients undergoing mechanical thrombectomy procedures using percutaneous devices.
Urokinase, Pro-urokinase, Alteplase, or Tenecteplase administered systemically or via catheter.
他の名前:
  • tPA, rt-PA, Urokinase, Tenecteplase

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
All-Cause Mortality at 30 Days
時間枠:30 days
The percentage of participants who die from any cause within 30 days of enrollment.
30 days
All-Cause Mortality at 90 Days
時間枠:90 days
The percentage of participants who die from any cause within 90 days of enrollment.
90 days
Right Ventricular to Left Ventricular (RV/LV) Ratio Improvement Rate at 48 Hours
時間枠:48 hours ± 6 hours
The proportion of participants with a reduction in RV/LV ratio ≥15% from baseline measured by CTPA or Echocardiography.
48 hours ± 6 hours

二次結果の測定

結果測定
メジャーの説明
時間枠
Major Bleeding Events
時間枠:48 hours, 7 days, 30 days, 90 days
Incidence of major bleeding defined by ISTH, GUSTO, or BARC criteria (including intracranial hemorrhage).
48 hours, 7 days, 30 days, 90 days
Clinical Deterioration
時間枠:48 hours, 7 days
Composite of hemodynamic instability, need for rescue therapy (escalation to thrombolysis/MT/ECMO), intubation, or PE-related death.
48 hours, 7 days
6-Minute Walk Test (6MWT) Distance
時間枠:30 days, 90 days
Change in walking distance from baseline (estimated) to follow-up. Minimal Clinically Important Difference (MCID) ≥30 meters.
30 days, 90 days
Post-VTE Functional Status (PVFS) Score
時間枠:30 days, 90 days
Assessment of functional limitation due to VTE (Scale 0-5).
30 days, 90 days
Quality of Life (PEmb-QoL)
時間枠:90 days

The questionnaire consists of 9 questions containing 40 items, which are organized into 6 domains:

Frequency of Complaints (FC): Assesses the frequency of respiratory and general symptoms (e.g., dyspnea, chest pain).

Daily Activity Limitations (AL): Measures limitations in performing activities of daily living (ADL).

Work-related Problems (WP): Evaluates difficulties in performing work or school duties.

Social Limitations (SL): Assesses restrictions on social activities. Intensity of Complaints (IC): Measures the severity of pain and breathlessness.

Emotional Complaints (EC): Captures anxiety, frustration, and fear related to the disease.

90 days
Symptomatic PE Recurrence
時間枠:90 days
Confirmed recurrent PE via CTPA or V/Q scan.
90 days
ICU Length of Stay
時間枠:From ICU admission to ICU discharge, assessed up to 30 days
Duration of intensive care unit stay during the index hospitalization
From ICU admission to ICU discharge, assessed up to 30 days
Total Hospital Length of Stay
時間枠:From hospital admission to hospital discharge, assessed up to 90 days
Duration of index hospitalization from emergency department admission to hospital discharge
From hospital admission to hospital discharge, assessed up to 90 days
Total Medical Costs
時間枠:Through 90 days
Direct medical costs incurred during index hospitalization and within 90 days of enrollment, including medications, procedures, and hospitalization
Through 90 days

その他の成果指標

結果測定
メジャーの説明
時間枠
Biomarker Improvement (Troponin, BNP, D-Dimer)
時間枠:48 hours, 7 days
Percentage reduction in cardiac biomarkers and D-Dimer levels.
48 hours, 7 days
Daily Step Count
時間枠:Continuous monitoring through 90 days
Average daily step count measured by smart band (e.g., Xiaomi/Huawei/Apple Watch) during the 90-day follow-up period. Assessed as a continuous variable (steps/day) and correlated with 6-Minute Walk Test distance and Post-VTE Functional Status score.
Continuous monitoring through 90 days

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年6月1日

一次修了 (推定)

2028年3月1日

研究の完了 (推定)

2029年12月31日

試験登録日

最初に提出

2026年3月24日

QC基準を満たした最初の提出物

2026年5月17日

最初の投稿 (実際)

2026年5月22日

学習記録の更新

投稿された最後の更新 (実際)

2026年5月22日

QC基準を満たした最後の更新が送信されました

2026年5月17日

最終確認日

2025年7月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

De-identified individual participant data (IPD) and data dictionaries will be made available to researchers upon reasonable request after the publication of the primary results.

IPD 共有時間枠

Starting 6 months after publication of the primary results, available for 5 years.

IPD 共有アクセス基準

Data will be shared with researchers who provide a methodologically sound proposal and whose use of data is for legitimate research purposes. Requests should be directed to the Principal Investigator.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

はい

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する